BNT113 + Pembrolizumab
Phase 2/3Recruiting 0 watching 0 views this week๐ Rising
62
Development Stage
โ
Pre-clinicalโ
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Unresectable Head and Neck Squamous Cell Carcinoma
Conditions
Unresectable Head and Neck Squamous Cell Carcinoma, Metastatic Head and Neck Cancer, Recurrent Head and Neck Cancer
Trial Timeline
Jan 7, 2021 โ Apr 1, 2029
NCT ID
NCT04534205About BNT113 + Pembrolizumab
BNT113 + Pembrolizumab is a phase 2/3 stage product being developed by BioNTech for Unresectable Head and Neck Squamous Cell Carcinoma. The current trial status is recruiting. This product is registered under clinical trial identifier NCT04534205. Target conditions include Unresectable Head and Neck Squamous Cell Carcinoma, Metastatic Head and Neck Cancer, Recurrent Head and Neck Cancer.
Hype Score Breakdown
Clinical
22
Activity
15
Company
7
Novelty
7
Community
8
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT04534205 | Phase 2/3 | Recruiting |
Competing Products
20 competing products in Unresectable Head and Neck Squamous Cell Carcinoma